<DOC>
	<DOCNO>NCT01738542</DOCNO>
	<brief_summary>A prospective study , proof-of concept , randomize , control , parallel group , simple blind perform 30 male patient ( 50-60 year old ) Intermittent Claudication ( Rutherford category 1-2 ) recently diagnose clinical manifestation exceed 6 month hypertension and/or dyslipidemia unique co-morbility disorder . After period stabilization claudication distance Stress test ( 12.5 % , 3.2 km/h ) 2 week , randomize 1:1 experimental arm ( Bosentan 62.5 mg twice daily/four week 125 mg twice daily/eight week ) control group .</brief_summary>
	<brief_title>Safety Efficacy Study Bosentan Intermittent Claudication Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Arterial hypertension hypercholesterolemia ABI &lt; 0,9 Positive claudiometry claudication distance 50 500 surgical patient Previous revascularization procedure Member study Smoker Uncontrolled hypertension Cardiac Stress Test unfinished Prior DVT Concomitant severe disease Obesity</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Bosentan</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
</DOC>